Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products
- 23 October 2020
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 23 (12) , 1599-1605
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 29 references indexed in Scilit:
- Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and OpportunitiesTransplantation and Cellular Therapy, 2016
- An overview of FDA-approved biologics medicinesDrug Discovery Today, 2015
- Factors affecting the uptake of new medicines: a systematic literature reviewBMC Health Services Research, 2014
- Biosimilar competition: lessons from EuropeNature Reviews Drug Discovery, 2014
- ON THE DEMAND FOR PRESCRIPTION DRUGS: HETEROGENEITY IN PRICE RESPONSESHealth Economics, 2012
- Testing for Structural Breaks in the Evaluation of ProgramsReview of Economics and Statistics, 2003
- Testing the Autocorrelation Structure of Disturbances in Ordinary Least Squares and Instrumental Variables RegressionsEconometrica, 1992
- A Simple, Positive Semi-Definite, Heteroskedasticity and Autocorrelation Consistent Covariance MatrixEconometrica, 1987
- Distribution of the Estimators for Autoregressive Time Series With a Unit RootJournal of the American Statistical Association, 1979
- TESTING FOR SERIAL CORRELATION IN LEAST SQUARES REGRESSION. IBiometrika, 1950